Suppr超能文献

癌基因-肿瘤抑制因子级联通过协调激活 Ras 和核因子-κB 驱动转移性前列腺癌。

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.

机构信息

Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

出版信息

Nat Med. 2010 Mar;16(3):286-94. doi: 10.1038/nm.2100. Epub 2010 Feb 14.

Abstract

Metastasis is responsible for the majority of prostate cancer-related deaths; however, little is known about the molecular mechanisms that underlie this process. Here we identify an oncogene-tumor suppressor cascade that promotes prostate cancer growth and metastasis by coordinately activating the small GTPase Ras and nuclear factor-kappaB (NF-kappaB). Specifically, we show that loss of the Ras GTPase-activating protein (RasGAP) gene DAB2IP induces metastatic prostate cancer in an orthotopic mouse tumor model. Notably, DAB2IP functions as a signaling scaffold that coordinately regulates Ras and NF-kappaB through distinct domains to promote tumor growth and metastasis, respectively. DAB2IP is suppressed in human prostate cancer, where its expression inversely correlates with tumor grade and predicts prognosis. Moreover, we report that epigenetic silencing of DAB2IP is a key mechanism by which the polycomb-group protein histone-lysine N-methyltransferase EZH2 activates Ras and NF-kappaB and triggers metastasis. These studies define the mechanism by which two major pathways can be simultaneously activated in metastatic prostate cancer and establish EZH2 as a driver of metastasis.

摘要

转移是导致大多数前列腺癌相关死亡的原因;然而,对于支持这一过程的分子机制知之甚少。在这里,我们确定了一个癌基因-肿瘤抑制因子级联,通过协调激活小 GTPase Ras 和核因子-kappaB(NF-kappaB)来促进前列腺癌的生长和转移。具体来说,我们表明 Ras GTPase 激活蛋白(RasGAP)基因 DAB2IP 的缺失会在原位小鼠肿瘤模型中诱导转移性前列腺癌。值得注意的是,DAB2IP 作为一种信号支架,通过不同的结构域协调调节 Ras 和 NF-kappaB,分别促进肿瘤生长和转移。DAB2IP 在人前列腺癌中受到抑制,其表达与肿瘤分级呈负相关,并预测预后。此外,我们报告说,DAB2IP 的表观遗传沉默是多梳蛋白组蛋白赖氨酸 N-甲基转移酶 EZH2 激活 Ras 和 NF-kappaB 并引发转移的关键机制。这些研究定义了两种主要途径在转移性前列腺癌中可以同时被激活的机制,并确立了 EZH2 作为转移的驱动因素。

相似文献

2
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
J Biol Chem. 2005 Jun 10;280(23):22437-44. doi: 10.1074/jbc.M501379200. Epub 2005 Apr 6.
4
DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):729-35. doi: 10.1016/j.ijrobp.2014.03.035. Epub 2014 May 24.
7
MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
Cancer Genet. 2012 Mar;205(3):113-23. doi: 10.1016/j.cancergen.2012.01.002.
9
EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival.
Clin Cancer Res. 2012 Aug 1;18(15):4048-58. doi: 10.1158/1078-0432.CCR-12-0399. Epub 2012 Jun 13.
10
EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Cancer Res. 2020 Oct 15;80(20):4371-4385. doi: 10.1158/0008-5472.CAN-20-0458. Epub 2020 Aug 19.

引用本文的文献

2
The role of ubiquitination and deubiquitination in urological tumours.
Front Pharmacol. 2025 Jul 23;16:1532878. doi: 10.3389/fphar.2025.1532878. eCollection 2025.
5
Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.
Funct Integr Genomics. 2025 Mar 6;25(1):53. doi: 10.1007/s10142-025-01563-8.
6
ATAD2 Drives Prostate Cancer Progression to Metastasis.
Mol Cancer Res. 2025 May 2;23(5):379-390. doi: 10.1158/1541-7786.MCR-24-0544.
7
Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer.
Trends Endocrinol Metab. 2025 Jan 2. doi: 10.1016/j.tem.2024.12.003.
9
Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer.
Microorganisms. 2024 Aug 12;12(8):1653. doi: 10.3390/microorganisms12081653.
10
Exploring the Genetic Landscape of Vitiligo in the Pura Raza Español Horse: A Genomic Perspective.
Animals (Basel). 2024 Aug 21;14(16):2420. doi: 10.3390/ani14162420.

本文引用的文献

1
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
Nature. 2009 Nov 5;462(7269):108-12. doi: 10.1038/nature08460. Epub 2009 Oct 21.
2
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.
Cancer Cell. 2009 Jul 7;16(1):44-54. doi: 10.1016/j.ccr.2009.05.009.
3
Microenvironmental regulation of metastasis.
Nat Rev Cancer. 2009 Apr;9(4):239-52. doi: 10.1038/nrc2618. Epub 2008 Mar 12.
5
BRAF activation initiates but does not maintain invasive prostate adenocarcinoma.
PLoS One. 2008;3(12):e3949. doi: 10.1371/journal.pone.0003949. Epub 2008 Dec 16.
6
Somatic mutations affect key pathways in lung adenocarcinoma.
Nature. 2008 Oct 23;455(7216):1069-75. doi: 10.1038/nature07423.
7
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4.
8
Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Mutat Res. 2008 Dec 1;647(1-2):21-9. doi: 10.1016/j.mrfmmm.2008.07.010. Epub 2008 Aug 3.
9
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Nat Genet. 2008 Jun;40(6):741-50. doi: 10.1038/ng.159. Epub 2008 May 18.
10
NF-kappaB and cancer-identifying targets and mechanisms.
Curr Opin Genet Dev. 2008 Feb;18(1):19-26. doi: 10.1016/j.gde.2008.01.020. Epub 2008 Apr 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验